Nizoblue (Ketoconazole)

Ketoconazole, the active ingredient in Nizoblue, is an imidazole antifungal presented as a topical formulation for skin use. It treats fungal skin infections such as tinea corporis, tinea cruris, seborrheic dermatitis, and pityriasis versicolor in adult patients.

GNH USA supplies Nizoblue as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketoconazole is an imidazole antifungal that targets dermatophyte and yeast infections of the skin.

- Tinea corporis: reduces lesion size, scaling and itching caused by dermatophyte infection. - Tinea cruris: clears fungal growth in the groin area, relieving redness and discomfort. - Seborrheic dermatitis: diminishes flaking and erythema associated with Malassezia overgrowth. - Pityriasis versicolor: eliminates the yeast responsible for pigmentary changes and fine scaling.

Ketoconazole topical therapy may cause local and systemic adverse reactions.

Common Side Effects: - Skin irritation: burning, stinging or mild pain at the application site. - Pruritus: increased itching of the treated area. - Redness: erythema surrounding the lesion. - Dryness or scaling of the skin.

Serious or Rare Side Effects: - Allergic contact dermatitis: severe rash, swelling or blistering. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: extensive skin detachment. - Hepatic toxicity: abnormal liver function tests when systemic absorption occurs.

Before using Nizoblue, consider the following safety measures.

- Assess hypersensitivity: avoid if the patient has known allergy to ketoconazole or imidazoles. - Avoid broken skin: do not apply on open wounds or severely inflamed areas. - Limit duration: follow the prescriber’s recommended treatment length to reduce risk of resistance. - Monitor systemic exposure: watch for signs of liver dysfunction with extensive use. - Store at room temperature: keep below 25 °C in the original container, protected from moisture and light.

Ketoconazole topical can interact with other agents, especially when systemic absorption is possible.

Major Interactions (Avoid): - Concurrent systemic azole antifungals (e.g., itraconazole): may increase systemic ketoconazole levels. - Strong CYP3A4 inhibitors applied over large areas: could raise systemic exposure.

Moderate Interactions (Monitor Closely): - Other topical irritants (e.g., corticosteroids) applied to the same site may increase skin irritation. - Alcohol‑based skin cleansers: may enhance percutaneous absorption. - Phototoxic agents: avoid excessive UV exposure after application.